Piratip is responsible for conducting research in specific technology areas for the firm. In particular, he leads RTW’s comprehensive effort in gene therapy and gene editing, which spans across public and private companies as well as within academic institutions.
Piratip joined RTW directly from academia in 2014. He received an MA in Biotechnology from Columbia University, and a BS in Biochemistry from McGill University.
In the past several years at RTW, I witnessed tremendous advancements in genetic medicines, culminating in the approvals of the first gene therapies. I am proud to be part of a community of healthcare innovators, that pushes the envelope of medical discoveries to serve patients afflicted by rare genetic diseases.